InvestorsHub Logo

sentiment_stocks

03/22/22 2:15 PM

#453335 RE: hyperopia #453314

Thanks for posting those past links of yours. The BATON system is interesting, but I'll admit, I don't quite understand how the system works, or would be applied in the treatment process. DCs carry antigens, not T cells... rather, they carry the antigens to the T cells, which activates them.

I'm curious how this system would work. It doesn't load the DCs with T cells, but with neoantigens? As I see it, if a tumor that's been removed and flash frozen had neoantigens on it, and DCVax-L is made from that, the vaccine, as it is made now, is loaded with those same Neo antigens.

And if Direct is used, and injected into a tumor with "neoantigens" (neoantigens being antigens that cannot be recognized as "self" - I believe? - that's perhaps, too simple an explanation), then the injected DCs will also pick up the neoantigens and antigens present in that particular tumor and run back to the T cells carrying those to again, activate those T cells.

So I'm curious if there is a moderately simple explanation that anyone can provide as to how this BATON system might work?

biosectinvestor

03/22/22 3:49 PM

#453390 RE: hyperopia #453314

I missed these posts Hyperopia. Or did not read closely.

Thanks for the further background.

Incredible stuff.

I agree with your take here:

“BTW - This is the system that Shashi Murthy was making presentations about dendritic cell manufacturing systems at conferences like Phacilitate, where I believe he caught the attention of Linda Powers, who potentially encouraged the development of the MicroDEN system.”

Makes more sense to me.